Mission

ICAN provides direct patient navigation services, molecular profiling and clinical trials advocacy, research services, and public education about the anticancer drug pipeline. ICAN focuses on Stage IV patients, spanning the gamut of cancer types-from the most commonly diagnosed solid tumors to the rarest of hematological malignancies and synchronous cancers. ICAN assists patients in accessing drugs via expanded access programs. The Exon 20 Group's grants ($290,000 in 2022) are targeted to specific cancer research laboratories. The organization specializes in complex cases, rare cancers, and cancers of unknown primary. ICAN handles patients with oncology teams in major cancer centers as well as patients who are uninsured, underinsured, and who have been underserved.